Kura Oncology (NASDAQ: KURA) reported Q1 EPS of ($0.66), $0.04 worse than the analyst estimate of ($0.62). Revenue for the quarter came in at $14.11 million versus the consensus estimate of $13.37 million.

For earnings history and earnings-related data on Kura Oncology (KURA) click here.